Philippines FDA Compliance

Discover OneScan

Global Regulations

Icon graphic element
Labelling

Products are required to display information in writing.

Graphic element
Unit Level Traceability

Sellable units are uniquely identified enabling a more granular traceability.

Summary

The Philippines does not currently operate a national pharma serialization and traceability system with mandatory end to end serial number reporting across the supply chain. Based on the Food and Drug Administration’s published requirements, the current enforceable framework is centered on product identification through a Global Trade Item Number, or GTIN, or an equivalent unique global product identification number, which must be included in product registration and carried on the product exterior or in a scannable identification graphic. (Food and Drug Administration)

The Philippine FDA also maintains digital platforms for product authorization and public product verification. These support registration and market verification, but they are not published as a national serialization event repository comparable to systems such as Tatmeen, EMVS, or MDLP. (eservices.fda.gov.ph)

Labelling Requirements 

Every registered pharmaceutical product must use a GTIN or an equivalent unique global product identification number as part of the FDA registration framework. The FDA states that this identifier may be represented in a barcode, QR code, or equivalent identification graphic, and that the product exterior, including packaging, labels, and containers, must bear the product identification number and or its equivalent graphic in a form that supports visual verification and scanning.

Published FDA requirements do not currently establish a nationwide mandatory rule for serialized 2D DataMatrix barcodes containing GTIN, serial number, batch number, and expiry date for all prescription medicines. The formal requirement published by FDA is product identification at the GTIN level.

Regulatory Timeline 

  • 2009: Republic Act No. 9711 strengthened the Philippine FDA and established its regulatory authority over health products. (Food and Drug Administration)
  • 2014: FDA Circular No. 2014-011 introduced the requirement to use a GTIN or equivalent unique global product identification number for FDA regulated products seeking registration. (Food and Drug Administration)
  • 30 June 2015: FDA Circular No. 2014-011 took effect.
  • 2023: FDA Circular No. 2023-008 required approved package inserts and patient information leaflets of registered drug products to be published in the FDA Verification Portal. (Food and Drug Administration)
  • 2025: FDA announced the launch of the new Verification Portal, reinforcing digital product verification for the market. (Food and Drug Administration)

Reporting Requirements 

FDA Reporting Table
Operation
Data to Report
When to Report
Product Registration
GTIN or equivalent unique global product identification number
During FDA product registration application
Establishment Authorization
Establishment identification details through FDA authorization process
During licensing and authorization through FDA systems (essences.fda.gov.ph)
Product Verification
Registered product details visible in FDA Verification Portal
After approval and publication in the portal (Food and Drug Administration)
Package Insert and PIL Publication
Approved PI and PIL for registered drug products
Published in the FDA Verification Portal and updated monthly under FDA Circular 2023-008 (Food and Drug Administration)

There is no published FDA requirement, in the sources reviewed, for routine national reporting of serial commissioning, aggregation, shipment events, receipt events, returns, or decommissioning for pharmaceutical products.

OperationData to ReportWhen to Report

Commission 
Aggregation 
Shipping 

GTIN, Serial, Batch, Expiry  
Parent SSCC, Child Serials  
Sender GLN, Receiver GLN, SSCC or Serial List
During packaging before shipment 
When creating cases or pallets 
Before dispatch 
ReceivingImport Clearance
Supply to Pharmacy
GTIN, Serial, Batch, Expiry  
Parent SSCC, Child Serials  
Sender GLN, Receiver GLN, SSCC or Serial List
During packaging before shipment 
When creating cases or pallets 
Before dispatch 
Returns 
Decommission 
Serial status and reference 
Reason and serials 
When return is approved 
When product is destroyed or removed 

Operational Timelines for Industry 

  • Obtain company authorization and product registration through the FDA eServices framework before placing product on the market. (eservices.fda.gov.ph)
  • Assign a GTIN or equivalent unique global product identification number to each product and include it in the FDA registration record.
  • Ensure the product exterior carries the identification number and or its scannable graphic in line with FDA requirements.
  • Confirm that approved product records are correctly reflected in the FDA Verification Portal after approval. (FDA Verification)
  • Maintain accurate product records, packaging data, and approved product information to support verification, market surveillance, and recall readiness. (Food and Drug Administration)

Reporting Hub

The Philippines FDA uses digital platforms for product registration and product verification:

  • FDA Verification Portal for public verification of licensed establishments and registered health products, including drug products. (Food and Drug Administration)

These portals support regulatory authorization and verification. As of the currently published FDA materials reviewed here, there is no published requirement for a national pharma event reporting hub that captures commission, aggregation, shipping, receiving, or decommission events at serial number level. This is an inference from the scope of the published FDA requirements and portals.

Aggregation Requirements 

There is no published nationwide FDA requirement, in the sources reviewed, mandating case or pallet aggregation for pharmaceutical products as part of a national traceability program. No published rule was identified requiring SSCC based parent child hierarchy reporting to a central national repository. This conclusion is based on the currently available FDA serialization and identification guidance reviewed here.

Common Errors to Avoid 

  • Using a GTIN that does not match the registered product record.
  • Treating the GTIN as a batch or lot number. The FDA explicitly states that product identification is not equivalent to a manufacturing batch or lot number.
  • Failing to place the product identification number or equivalent scannable graphic on the product exterior.
  • Assuming that the Philippines currently requires full serial level reporting similar to markets with mature national traceability hubs. The currently published FDA framework reviewed here is product identification focused, not a published end to end national serial event reporting model.
  • Not validating whether the registered product, package insert, and patient information leaflet appear correctly in the FDA Verification Portal. (Food and Drug Administration)

Trusted by Industry Leaders

Smooth and Successful

LSPedia didn’t just provide software; they ensured we were fully compliant. Anytime we had questions, the LSPedia team knew DSCSA inside and out and guided us step by step. That level of expertise made a huge difference during audits. Thanks to their expert team our audit was smooth and successful

Hussein Salman
Lead Pharmacist, Pioneer Pharmacy Services

Constant Commitment

LSPedia shows a constant commitment to improvement; whether it's their support or their product...they're always leveling up. The support team provides consistently thorough follow-up and clear, articulate communication. the support we receive represents a meaningful step up in service and is genuinely appreciated.

Zac Sweeny
EPCIS Data Encoder,Capital Wholesale Drug
Read All TestimonialsView Our Customers

Fill in the form for latest updates

Get in Touch

We invite you to learn more about how LSPedia can support your compliance and supply chain needs. For more information about our solutions, partnership opportunities, or to speak with one of our experts.

Contact Us